{"url":"https://lda.senate.gov/api/v1/filings/b032a4f8-e07a-48ed-b058-abb07e78234c/","filing_uuid":"b032a4f8-e07a-48ed-b058-abb07e78234c","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/b032a4f8-e07a-48ed-b058-abb07e78234c/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeff Ricchetti","dt_posted":"2025-04-16T14:23:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 13th Street, NW","registrant_address_2":"Suite 830N","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":62778,"url":"https://lda.senate.gov/api/v1/registrants/62778/","house_registrant_id":35395,"name":"RICCHETTI INCORPORATED","description":"Lobbying and consulting","address_1":"601 13th Street, NW","address_2":"Suite 830N","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JEFF RICCHETTI","contact_telephone":"+1 202-879-9382","dt_updated":"2026-07-13T18:17:38.137744-04:00"},"client":{"id":210847,"url":"https://lda.senate.gov/api/v1/clients/210847/","client_id":1004912,"name":"IPSEN BIOPHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-06-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":30648,"prefix":null,"prefix_display":null,"first_name":"JEFF","nickname":null,"middle_name":null,"last_name":"RICCHETTI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to coverage of diagnostic testing for cancer; H.R.842/S.339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":30648,"prefix":null,"prefix_display":null,"first_name":"JEFF","nickname":null,"middle_name":null,"last_name":"RICCHETTI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}